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Genes encoding multiples forms of phospholipase A
2
 are expressed in immature forms 
of human leukemic blasts 
 
Letter to the Editor 
 
Phospholipase A
2
 (PLA
2
) catalyzes the hydrolysis of the sn-2 position of membrane 
glycerophospholipids to liberate the eicosanoid precursor arachidonic acid (AA).
1,2
 Three 
distinct families have been documented: low molecular weight soluble forms of PLA
2
 
(sPLA
2
); Ca
2+
-dependent high molecular weight PLA
2
 (cPLA
2
); and Ca
2+
-independent high 
molecular weight PLA
2
 (iPLA
2
). The sPLA
2
 family is implicated in several biological 
processes such as inflammation and host defense.
1,2
 Nine isoenzymes have been identified. 
Among them sPLA
2
-IB is the pancreatic one. sPLA
2
-IIA is constitutively expressed in 
various organs related to immune response such as bone marrow spleen and thymus. sPLA
2
-
V is found in several immune cells such as macrophage, mast cells and type II helper T 
cells. sPLA
2
-X is expressed in the digestive tract, immune organs and blood leukocytes. The 
cPLA
2
 family consisted of four members, cPLA
2
-IVA, cPLA
2
-IVB, cPLA
2
-IVC, cPLA
2
-
IVD; cPLA
2
-IVA being the central regulator of stimulus-coupled cellular AA release.
1,2
 The 
iPLA
2
 (PLA
2
-VI) plays a major role in phospholipids remodeling. 
 Eicosanoid products of the cyclooxygenase (COX) and lipoxygenase (LOX) 
pathways of AA are important mediators of malignant proliferation.
3
 Deregulated PLA
2
 
activity contributes to the pathogenesis of several malignancies including prostate cancer, 
ovarian carcinoma and colorectal adenocarcinoma.
1,2
 The COX and LOX pathways of AA 
have been recently documented on immature leukemic blasts of patients with acute myeloid 
(AML) and acute lymphoid (ALL) leukaemia.
4,5
 Thus, freshly isolated AML and ALL 
blasts express COX-1, produce the AA metabolite prostaglandin E
2
 (PGE
2
), express 
 2 
functional EP
2
 receptors and increase their growth in response to exogenously added PGE
2
. 
The World Health Organization (WHO) has proposed a classification system divides AML 
into several broad groups: AML with genetic abnormalities, AML with multilineage 
dysplasia, AML related to previous chemotherapy or radiation and AML not otherwise 
specified. The latter group contains a subgroup, AML without maturation, which consisted 
of the weaker immature blast group. In view of the potentially important oncogenic action 
of PLA
2
 in leukemic proliferation, quantitative polymerase chain reaction (Q-PCR) was 
utilized to determine which of PLA
2
 mRNAs were expressed in AML blasts without 
maturation and ALL blasts. 
Blood samples recovered on EDTA were obtained from twenty one AML patients and ten B 
ALL patients at diagnosis according to the Helsinki recommendations. AML patients 
consisted in a homogeneous group of patients with blasts without signs of maturation and 
no genetic abnormality. Blood samples with more than 85% blast cells as circulating 
leukocytes were used. Leucocytosis ranged from 10 to 219 G/l. Immediately after recovery 
leukemic blasts were isolated by separation on a Ficoll gradient and washed one time with 
Hank’s balanced salts solution (HBSS). The blast purity (>98%) was controlled by flow 
cytometry analysis. Blast viability (>95%) was judged by trypan blue exclusion. Blast RNA 
was immediately extracted with Tripure (Roche GmbH, Mannheim, Germany) and was 
stored at -80°C until used. As a control group, blood samples were recovered from 7 healthy 
volunteers. Control blood mononuclear cells were recovered and processed exactly as for 
leukemic blast samples. 
 In a first set of experiments we investigated if mRNAs derived from the four cPLA
2
 
genes were detected in AML and ALL leukemic blasts. As shown in Figure 1 (left part), 
mRNAs derived from three of the four cloned cPLA
2
 genes are detected in human leukemic 
blasts. PLA
2
-IVD transcripts were not present at detectable levels in AML and ALL 
 3 
leukemic blasts and in blood mononuclear cells from healthy individuals (data not shown). 
In contrast, PLA
2
-IVA, PLA
2
-IVB and PLA
2
-IVC were detected. Similar amounts of PLA
2
-
IVB and PLA
2
-IVC transcripts were found in AML and ALL blasts and control cells. Both 
enzymes show little specificity for the sn-2 fatty acid.
1,2
 In contrast, PLA
2
-IVA transcripts 
were markedly (p=0.006) reduced in ALL blasts as compared with blood mononuclear cells. 
PLA
2
-IVA preferentially hydrolyses phospholipids containing AA at the sn-2 position. 
PLA
2
-IVA is ubiquitously and constitutively expressed in most cells and tissues. One 
notable exception is mature B and T cells which do not contain detectable levels of PLA
2
-
IVA.
1
 Q-PCR analysis reveals that PLA
2
-IVA levels were also markedly lowered in 
immature forms of ALL blasts. The high levels of AA documented in ALL blasts have been 
previously related to an elevated ∆6 desaturase activity.6 Low levels of PLA
2
-IVA in ALL 
blasts might also explain these elevated AA amounts. PLA
2
-VI (iPLA
2
) transcript levels 
were higher (p=0.003) in AML and ALL leukemic blasts. PLA
2
-VI was originally reported 
to mediate phospholipids remodelling and, thus, to act as a housekeeping protein without 
significant roles in cell growth.
1,2
 Several recent studies have demonstrated that PLA
2
-VI 
exhibited roles in cell regulation, growth and death. Especially, one mechanism by which 
PLA
2
-VI mediates cell growth involves regulation of AA release, P53 and MAPK 
activation.
7
 A role for PLA
2
-VI may be suggested in the growth of AML and ALL blasts. 
The technique employed in this study allowed measurement of the absolute levels of any 
mRNA. So it was possible to evaluate the levels of each of the isoforms relative to one 
another. Results indicated the following rank of magnitude for cPLA
2
 in leukemic blasts: 
PLA
2
-VI > PLA
2
-IVA = PLA
2
-IVB > PLA
2
-IVC. Together, these observations might 
suggest PLA
2
-VI as a novel and interesting target for drug development for leukemic 
therapy. However, given the ubiquitous expression of PLA
2
-VI and its role in 
glycerophospholipid metabolism, drug strategies targeting PLA
2
-VI must exhibit selectivity 
 4 
to avoid undesired side effects. 
 In another set of experiments we investigated if mRNAs derived from the nine 
sPLA
2
 genes (i.e PLA
2
-IB, PLA
2
-IIA, PLA
2
-IID, PLA
2
-IIE, PLA
2
-IIF, PLA
2
-III, PLA
2
-V, 
PLA
2
-X and PLA
2
-XII) were detected in AML and ALL leukemic blasts. PLA
2
-IIE and 
PLA
2
-III were not present at detectable levels in AML and ALL leukemic blasts and control 
blood mononuclear cells (data not shown). In contrast transcripts for other sPLA
2
 subtypes 
could be detected (Figure 1, right part). Results indicated the following rank of magnitude 
for sPLA
2
 in leukemic blasts: PLA
2
-IB > PLA
2
-XII > PLA
2
-X > PLA
2
-IID > PLA
2
-IIA = 
PLA
2
-V > PLA2-IIF. Levels of PLA
2
-IB and PLA
2
-X transcripts were higher (p=0.0001) in 
AML blasts than in control cells. In contrast PLA
2
-IIA (p=0.0005), PLA
2
-IID (p=0.0007) 
and PLA
2
-V (p=0.0009) were markedly reduced while PLA
2
-XII and PLA
2
-IIF ones were 
unchanged. PLA
2
-X transcripts were higher (p=0.0006) in ALL blasts than in control cells. 
In contrast PLA
2
-IIA transcripts levels were reduced (p=0.001) while PLA
2
-IB, PLA
2
-IID, 
PLA
2
-IIF, PLA
2
-V and PLA
2
-XII ones were unchanged. Such variations of PLA
2
 subtypes 
would be of importance for leukemic patients. Thus, coagulation activation was often 
observed in patients with acute leukaemia. PLA
2
-IIA, PLA
2
-IID and PLA
2
-V, which 
possess potent anticoagulant activity,
1
 are markedly lowered in AML patients suggesting a 
putative link between PLA
2
 activity and coagulation disorders. Bacterial and fungal 
infections are the major cause of morbidity and mortality in acute leukemic patients. A 
decreased PLA
2
-IIA activity which has physiologically significant bactericidal activity,
1,2
 
and a decreased PLA
2
-V one that plays a role in innate immunity against fungal invasion
1,2
 
might be implicated in these infections. Numerous evidences have highlighted that cytosolic 
PLA
2
-IVA is the key enzyme for AA release from phospholipids of mammalian cells; AA 
being the first step for the biosynthesis of eicosanoids. Only those sPLA
2
 species that have a 
high specific activity of phospholipids hydrolysis and that can bind well to 
 5 
phosphatidylcholine-rich membranes, the PLA
2
-V and PLA
2
-X, have the capacity to release 
fatty acids when added to mammalian cells. As shown in Figure 1, the increase of PLA
2
-X 
transcripts in leukemic blasts is higher than the decrease of their PLA
2
-V transcripts. Thus, 
as lipolytic enzyme, PLA
2
-X might contribute to the generation of lipid mediators. Of 
interest PGE
2
, a COX metabolite of AA, was recently reported to stimulate the growth of 
leukemic blasts through and EP
2
 receptor dependent pathway.
4
 
 These results demonstrate that mRNA from four out of five cytosolic PLA
2
 (PLA
2
-
IVA, PLA
2
-IVB, PLA
2
-IVC and PLA
2
-VI) and six out of nine sPLA
2
 (PLA
2
-IB, PLA
2
-IIA, 
PLA
2
-IID, PLA
2
-V, PLA
2
-X and PLA
2
-XII) are present in leukemic blasts and that their 
mRNA transcript levels exhibited important variations as compared to blood mononuclear 
cells (summarized in Table I). One of the more notable finding is that leukemic blasts 
expressed high amounts of PLA
2
-VI and PLA
2
-X. This could be extremely significant as 
these two enzymatic activities play a major role in AA release for the generation of COX 
and LOX derived lipid mediators. In conclusion these results indicate that immature forms 
of leukemic AML and ALL blasts have the potential to express multiple isoforms of cPLA
2
 
and sPLA
2
 which could be of importance given the potential role of these enzyme activities 
in inflammation, generation of lipidic mediators, anticoagulant activity and bacterial 
infection. Investigation of PLA
2
 transcripts in other AML such as AML with genetic 
abnormalities and with multilineage dysplasia deserve now to be investigated. 
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Legend to Figure 1 
 
Q-PCR analysis of cytosolic PLA
2
 and soluble PLA
2
 transcripts in leukemic blasts. 
Q-PCR was performed in duplicate by using TaqMan assay reagents according to the 
manufacturer’s recommendations (Applied Biosystems, Foster City, CA) (product 
references - PLA
2
-IB: Hs00386701-m1; PLA
2
-IIA: Hs00179898-m1; PLA
2
-IID: 
Hs00173860-m1; PLA
2
-IIF: Hs00224482; PLA
2
-IVA: Hs00233352-m1; PLA
2
-IVB: 
Hs00979952-m1; PLA
2
-IVC: Hs00234345-m1; PLA
2
-IVD: Hs00603557-m1; PLA
2
-V: 
Hs00173472-m1; PLA
2
-VI: Hs001/85926-m1; PLA
2
-X: Hs00358567-m1; PLA
2
-XII: 
Hs00830106-s1). Gene expression levels were normalized to 18S RNA (product reference 
Hs99999901-s1). Amounts of various transcripts were compared to sample with the lowest 
level of transcripts (a patient who was arbitrary quoted 1). (●) indicates patients with no 
detectable transcript. Significance was assessed by using the Kruskal-Wallis test followed 
by a Mann-Whitney U-test. A Bonferroni adjustment indicated a p<0.016 as significant. 
 
Table 1 
 
 Soluble PLA
2
 Cytosolic PLA
2
 
 IB IIA IID IIE IIF III V X XII IVA IVB IVC IVD VI 
Controls Yes Yes Yes No No No Yes Yes Yes Yes Yes Yes No Yes 
ALL ↔ ↓ ↔ No ↔ No ↔ ↑ ↔ ↓ ↔ ↔ No ↑ 
AML ↑ ↓ ↓ No ↔ No ↓ ↑ ↔ ↔ ↔ ↔ No ↑ 
 
Comparison of soluble PLA
2
 and cytosolic PLA
2
 transcripts levels in ALL blasts, AML blasts 
and control blood mononuclear cells. “Yes” and “No” indicated the presence and the absence 
of transcripts, respectively. “↔,↑,↓” indicated similar, elevated and decreased levels of 
transcripts as compared to blood mononuclear cell, respectively. 
 

